Australia has become the first country to recognise psychedelics as medicines, after the Therapeutic Goods Administration took researchers by surprise and approved the psychedelic substances in magic mushrooms and MDMA for use by people with certain mental health conditions.
MDMA and psilocybin, the active ingredient in magic mushrooms, will be considered schedule 8 drugs - meaning they’re approved for controlled use when prescribed by a psychiatrist - from July this year after the TGA acknowledged there were few other options for patients with specific treatment-resistant mental illnesses.
Psilocybin, the active ingredient in magic mushrooms, has been approved for treatment-resistant depression.
The changes will allow MDMA to be used to treat post-traumatic stress disorder, and psilocybin for treatment-resistant depression.
They will still be considered prohibited substances - or schedule 9 drugs - for all other usages.
“Prescribing will be limited to psychiatrists, given their specialised qualifications and expertise to diagnose and treat patients with serious mental health conditions,” a TGA statement published on Friday said.
Psychiatrists will also first need to be approved by the TGA’s authorised prescriber scheme. »
